Tranylcypromine and Ziprasidone interaction

Tranylcypromine and Ziprasidone: both prescribing labels flag this combination with the strongest language, such as a contraindication, a boxed warning, or an instruction to avoid it.

Major

Do not combine without a prescriber's guidance. The label language below is the strongest FDA uses.

What the FDA labels say

From the Ziprasidone (Geodon) label · effective 2025-01-13

Major

• Concomitant use of monoamine oxidase inhibitors (MAOIs), or use within 14 days of stopping MAOIs.

Contraindicationsby drug classView label on DailyMed
Major

Monoamine Oxidase Inhibitors (MAOIs) Ziprasidone is contraindicated in patients taking, or within 14 days of stopping, MAOIs (including the MAOIs linezolid and intravenous methylene blue) because of an increased risk of serotonin syndrome [see Warnings and Precautions (5.4) , Drug Interaction (7.3) ] .

Contraindicationsby drug classView label on DailyMed
Major

• Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone.

Warnings and precautionsby drug classView label on DailyMed
Major

The concomitant use of GEODON with MAOIs is contraindicated.

Warnings and precautionsby drug classView label on DailyMed
Major

If concomitant use of GEODON with other serotonergic drugs is clinically warranted, inform patients of the increased risk of serotonin syndrome and monitor for symptoms .

Warnings and precautionsby drug classView label on DailyMed

From the Tranylcypromine (Tranylcypromine Sulfate) label · effective 2025-07-25

Moderate

Excessive reduction of blood glucose (additive effect) f CNS depressant agents (including opioids, alcohol, sedatives, hypnotics) Use with caution d Increased CNS depression Dietary supplements containing sympathomimetics Contraindicated a Antidepressants including but not limited to: Other MAOIs (e.g., linezolid, intravenous methylene blue, selective MAOIs)…

Drug interactionsby drug classView label on DailyMed
Minor

In some cases of an interaction between tranylcypromine sulfate tablets and SSRIs or SNRIs, the features of the syndrome resembled neuroleptic malignant syndrome.

Warnings and precautionsby drug classView label on DailyMed

Taking more than these two? Interactions stack. Check your whole list at once; it stays in your browser.

Open in the checker

Not medical advice. Interaction Checker quotes FDA label text and NIH fact sheets. Whether an interaction matters for you depends on doses, timing, kidney and liver function, and other conditions. Confirm with a pharmacist or prescriber.